Zoetis (ZTS) Revenue & Revenue Breakdown
Zoetis Revenue Highlights
Latest Revenue (Y)
$8.54B
Latest Revenue (Q)
$2.36B
Main Segment (Y)
Total Products and Services
Main Geography (Y)
Total Geographical Area
Zoetis Revenue by Period
Zoetis Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $8.54B | 5.74% |
| 2022-12-31 | $8.08B | 3.91% |
| 2021-12-31 | $7.78B | 16.49% |
| 2020-12-31 | $6.67B | 6.63% |
| 2019-12-31 | $6.26B | 7.47% |
| 2018-12-31 | $5.83B | 9.76% |
| 2017-12-31 | $5.31B | 8.57% |
| 2016-12-31 | $4.89B | 2.58% |
| 2015-12-31 | $4.76B | -0.42% |
| 2014-12-31 | $4.79B | 4.91% |
| 2013-12-31 | $4.56B | 5.19% |
| 2012-12-31 | $4.34B | 2.43% |
| 2011-12-31 | $4.23B | 18.17% |
| 2010-12-31 | $3.58B | 29.78% |
| 2009-12-31 | $2.76B | - |
Zoetis generated $8.54B in revenue during NA 2023, up 5.74% compared to the previous quarter, and up 146.68% compared to the same period a year ago.
Zoetis Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $2.36B | 7.81% |
| 2024-03-31 | $2.19B | -1.04% |
| 2023-12-31 | $2.21B | 2.88% |
| 2023-09-30 | $2.15B | -1.33% |
| 2023-06-30 | $2.18B | 9.00% |
| 2023-03-31 | $2.00B | -1.96% |
| 2022-12-31 | $2.04B | 1.90% |
| 2022-09-30 | $2.00B | -2.44% |
| 2022-06-30 | $2.05B | 3.32% |
| 2022-03-31 | $1.99B | 0.97% |
| 2021-12-31 | $1.97B | -1.16% |
| 2021-09-30 | $1.99B | 2.16% |
| 2021-06-30 | $1.95B | 4.12% |
| 2021-03-31 | $1.87B | 3.54% |
| 2020-12-31 | $1.81B | 1.18% |
| 2020-09-30 | $1.79B | 15.37% |
| 2020-06-30 | $1.55B | 0.91% |
| 2020-03-31 | $1.53B | -8.36% |
| 2019-12-31 | $1.67B | 5.68% |
| 2019-09-30 | $1.58B | 2.39% |
| 2019-06-30 | $1.55B | 6.32% |
| 2019-03-31 | $1.46B | -6.97% |
| 2018-12-31 | $1.56B | 5.68% |
| 2018-09-30 | $1.48B | 4.59% |
| 2018-06-30 | $1.42B | 3.59% |
| 2018-03-31 | $1.37B | -6.44% |
| 2017-12-31 | $1.46B | 8.39% |
| 2017-10-01 | $1.35B | 6.15% |
| 2017-07-02 | $1.27B | 3.09% |
| 2017-04-02 | $1.23B | -3.60% |
| 2016-12-31 | $1.28B | 2.90% |
| 2016-10-02 | $1.24B | 2.73% |
| 2016-07-03 | $1.21B | 3.96% |
| 2016-04-03 | $1.16B | -8.79% |
| 2015-12-31 | $1.27B | 4.94% |
| 2015-09-27 | $1.21B | 3.32% |
| 2015-06-28 | $1.18B | 6.62% |
| 2015-03-29 | $1.10B | -16.52% |
| 2014-12-31 | $1.32B | 9.09% |
| 2014-09-28 | $1.21B | 4.49% |
| 2014-06-29 | $1.16B | 5.56% |
| 2014-03-30 | $1.10B | -12.52% |
| 2013-12-31 | $1.25B | 13.69% |
| 2013-09-29 | $1.10B | -0.99% |
| 2013-06-30 | $1.11B | 2.20% |
| 2013-03-31 | $1.09B | -7.31% |
| 2012-12-31 | $1.18B | 15.41% |
| 2012-09-30 | $1.02B | -6.86% |
| 2012-06-30 | $1.09B | 4.49% |
| 2012-03-31 | $1.05B | -7.10% |
| 2011-12-31 | $1.13B | 7.44% |
| 2011-09-30 | $1.05B | -2.33% |
| 2011-06-30 | $1.07B | 9.26% |
| 2011-03-31 | $983.00M | - |
Zoetis generated $2.36B in revenue during Q2 2024, up 7.81% compared to the previous quarter, and up 118.05% compared to the same period a year ago.
Zoetis Revenue Breakdown
Zoetis Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Other Pharmaceuticals | $1.28B | - | - | - | - |
| Vaccines | $1.77B | - | - | - | - |
| Total Products and Services | $8.47B | - | - | - | - |
| Parasiticides | $1.95B | - | - | - | - |
| Other Non Pharmaceuticals | $254.00M | - | - | - | - |
| Medicated Feed Additives | $354.00M | - | - | - | - |
| Dermatology | $1.43B | - | - | - | - |
| Contract Manufacturing and Human Health Diagnostics | $78.00M | $86.00M | $82.00M | $83.00M | $85.00M |
| Anti-infective Products | $1.06B | - | - | - | - |
| Animal Health Diagnostics | $376.00M | - | - | - | - |
Zoetis's latest annual revenue breakdown by segment (product or service), as of Dec 23: Total Products and Services (49.77%), Parasiticides (11.45%), Vaccines (10.41%), Dermatology (8.39%), Other Pharmaceuticals (7.52%), Anti-infective Products (6.21%), Animal Health Diagnostics (2.21%), Medicated Feed Additives (2.08%), Other Non Pharmaceuticals (1.49%), and Contract Manufacturing and Human Health Diagnostics (0.46%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horses | $66.00M | $5.09B | $60.00M | $65.00M | $72.00M | $4.75B | $58.00M | $63.00M | $64.00M | $4.24B | $60.00M | $68.00M | $60.00M | $3.29B | - | - | - | - | - | - |
| Cattle | $391.00M | $401.00M | $374.00M | $329.00M | $399.00M | $377.00M | $371.00M | $328.00M | $364.00M | $413.00M | $403.00M | $342.00M | $399.00M | $451.00M | - | - | - | - | - | - |
| Dogs and Cats | $1.38B | - | $1.35B | $1.42B | $1.15B | $-3.45B | $1.21B | $1.30B | $1.20B | $-3.06B | $1.14B | $1.16B | $1.02B | $-2.31B | - | - | - | - | - | - |
| Fish | $45.00M | $62.00M | $57.00M | $52.00M | $49.00M | $61.00M | $60.00M | $47.00M | $44.00M | $55.00M | $56.00M | $39.00M | $37.00M | $47.00M | - | - | - | - | - | - |
| Poultry | $139.00M | $127.00M | $127.00M | $131.00M | $139.00M | $115.00M | $116.00M | $121.00M | $124.00M | $118.00M | $124.00M | $134.00M | $131.00M | $125.00M | - | - | - | - | - | - |
| Swine | $127.00M | $139.00M | $129.00M | $133.00M | $142.00M | $138.00M | $129.00M | $144.00M | $154.00M | $155.00M | $153.00M | $161.00M | $190.00M | $167.00M | - | - | - | - | - | - |
| Other Pharmaceuticals | - | $358.00M | $313.00M | $315.00M | $294.00M | $272.00M | $252.00M | $265.00M | $254.00M | $249.00M | $243.00M | $248.00M | $226.00M | $224.00M | $208.00M | $192.00M | $197.00M | - | - | - |
| Parasiticides | - | $947.00M | $568.00M | $432.00M | $443.00M | $422.00M | $536.00M | $459.00M | $389.00M | $396.00M | $460.00M | $390.00M | $306.00M | - | - | - | - | - | - | - |
| Total Products and Services | - | $4.32B | $2.16B | $1.98B | $2.01B | $1.98B | $2.03B | $1.97B | $1.94B | $1.97B | $1.93B | $1.85B | $1.78B | - | - | - | - | - | - | - |
| Vaccines | - | $912.00M | $430.00M | $429.00M | $418.00M | $449.00M | $446.00M | $405.00M | $422.00M | $421.00M | $417.00M | $413.00M | $390.00M | - | - | - | - | - | - | - |
| Animal Health Diagnostics | - | $187.00M | $96.00M | $93.00M | $85.00M | $83.00M | $87.00M | $98.00M | $91.00M | $95.00M | $99.00M | $89.00M | $89.00M | - | - | - | - | - | - | - |
| Anti-infective Products | - | $525.00M | $244.00M | $288.00M | $279.00M | $284.00M | $233.00M | $285.00M | $306.00M | $329.00M | $259.00M | $321.00M | $336.00M | - | - | - | - | - | - | - |
| Dermatology | - | $776.00M | $359.00M | $292.00M | $351.00M | $348.00M | $319.00M | $311.00M | $321.00M | $326.00M | $285.00M | $248.00M | $260.00M | - | - | - | - | - | - | - |
| Medicated Feed Additives | - | $183.00M | $84.00M | $87.00M | $99.00M | $78.00M | $85.00M | $98.00M | $106.00M | $99.00M | $103.00M | $112.00M | $124.00M | - | - | - | - | - | - | - |
| Other Non Pharmaceuticals | - | $122.00M | $64.00M | $68.00M | $66.00M | $63.00M | $63.00M | $58.00M | $58.00M | $60.00M | $57.00M | $56.00M | $55.00M | - | - | - | - | - | - | - |
| Manufactured Product, Other | - | - | $29.00M | $26.00M | $29.00M | $19.00M | $32.00M | $28.00M | $19.00M | $19.00M | $31.00M | $23.00M | $22.00M | $16.00M | - | - | - | - | - | - |
| Livestock | - | - | $716.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Companion Animal | - | - | $1.41B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Contract Manufacturing and Human Health Diagnostics | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $22.00M | $19.00M | $19.00M |
Zoetis's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Dogs and Cats (64.31%), Cattle (18.17%), Poultry (6.46%), Swine (5.90%), Horses (3.07%), and Fish (2.09%).
Zoetis Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| BRAZIL | $393.00M | $330.00M | $312.00M | $258.00M | $293.00M |
| AUSTRALIA | $323.00M | $289.00M | $259.00M | $207.00M | $196.00M |
| UNITED STATES | $4.55B | $4.31B | $4.04B | $3.56B | $3.20B |
| Total Geographical Area | $8.47B | $7.99B | $7.69B | $6.59B | $6.17B |
| SPAIN | $122.00M | $118.00M | $128.00M | $112.00M | $114.00M |
| MEXICO | $162.00M | $136.00M | $133.00M | $116.00M | $117.00M |
| JAPAN | $158.00M | $173.00M | $186.00M | $177.00M | $158.00M |
| ITALY | $121.00M | $111.00M | $115.00M | $90.00M | $112.00M |
| GERMANY | $202.00M | $176.00M | $183.00M | $159.00M | $153.00M |
| FRANCE | $142.00M | $126.00M | $132.00M | $118.00M | $117.00M |
| CHINA | $320.00M | $382.00M | $357.00M | $266.00M | $200.00M |
| CHILE | $140.00M | $141.00M | $136.00M | $100.00M | - |
| CANADA | $255.00M | $238.00M | $232.00M | $210.00M | $206.00M |
Zoetis's latest annual revenue breakdown by geography, as of Dec 23: Total Geographical Area (55.12%), UNITED STATES (29.66%), BRAZIL (2.56%), AUSTRALIA (2.10%), CHINA (2.08%), CANADA (1.66%), GERMANY (1.32%), MEXICO (1.05%), JAPAN (1.03%), FRANCE (0.92%), CHILE (0.91%), SPAIN (0.79%), and ITALY (0.79%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JAPAN | $37.00M | $38.00M | $34.00M | $47.00M | $39.00M | $36.00M | $37.00M | $41.00M | $59.00M | $46.00M | $43.00M | $50.00M | $47.00M | $44.00M | $39.00M | $53.00M | $41.00M | $40.00M | $39.00M | $37.00M |
| ITALY | $28.00M | $34.00M | $26.00M | $35.00M | $26.00M | $25.00M | $24.00M | $32.00M | $30.00M | $28.00M | $30.00M | $32.00M | $25.00M | $27.00M | $28.00M | $14.00M | $21.00M | $30.00M | $26.00M | $28.00M |
| SPAIN | $32.00M | $28.00M | $30.00M | $31.00M | $33.00M | $21.00M | $29.00M | $35.00M | $33.00M | $31.00M | $33.00M | $33.00M | $31.00M | $29.00M | $31.00M | $24.00M | $28.00M | $28.00M | $29.00M | $27.00M |
| FRANCE | $41.00M | $40.00M | $34.00M | $34.00M | $34.00M | $35.00M | $28.00M | $31.00M | $32.00M | $34.00M | $31.00M | $32.00M | $35.00M | $36.00M | $29.00M | $24.00M | $29.00M | $34.00M | $24.00M | $32.00M |
| CHINA | $76.00M | $65.00M | $69.00M | $84.00M | $102.00M | $91.00M | $92.00M | $96.00M | $103.00M | $68.00M | $72.00M | $94.00M | $123.00M | $68.00M | $66.00M | $66.00M | $66.00M | $44.00M | $40.00M | $60.00M |
| CHILE | $31.00M | $31.00M | $31.00M | $39.00M | $39.00M | $35.00M | $31.00M | $34.00M | $41.00M | $36.00M | $32.00M | $34.00M | $34.00M | $28.00M | $24.00M | $25.00M | - | - | - | - |
| CANADA | $61.00M | $72.00M | $63.00M | $70.00M | $50.00M | $66.00M | $56.00M | $67.00M | $49.00M | $63.00M | $56.00M | $67.00M | $46.00M | $66.00M | $50.00M | $54.00M | $40.00M | $64.00M | $47.00M | $41.00M |
| BRAZIL | $101.00M | $117.00M | $101.00M | $91.00M | $84.00M | $97.00M | $70.00M | $86.00M | $77.00M | $85.00M | $78.00M | $75.00M | $74.00M | $77.00M | $62.00M | $56.00M | $63.00M | $87.00M | $72.00M | $60.00M |
| AUSTRALIA | $73.00M | $75.00M | $84.00M | $82.00M | $82.00M | $64.00M | $80.00M | $80.00M | $65.00M | $63.00M | $70.00M | $69.00M | $57.00M | $53.00M | $60.00M | $51.00M | $43.00M | $46.00M | $53.00M | $48.00M |
| UNITED STATES | $1.16B | $1.21B | $1.17B | $1.17B | $1.00B | $1.11B | $1.09B | $1.09B | $1.02B | $1.04B | $1.06B | $1.00B | $933.00M | $952.00M | $996.00M | $823.00M | $786.00M | $861.00M | $844.00M | $718.00M |
| MEXICO | $44.00M | $43.00M | $42.00M | $38.00M | $39.00M | $35.00M | $33.00M | $33.00M | $35.00M | $35.00M | $31.00M | $34.00M | $33.00M | $32.00M | $26.00M | $26.00M | $32.00M | $30.00M | $29.00M | $28.00M |
| Total Geographical Area | $2.17B | $2.19B | $2.13B | $2.16B | $1.98B | $2.01B | $1.98B | $2.03B | $1.97B | $1.94B | $1.97B | $1.93B | $1.85B | $1.78B | $1.76B | $1.53B | $1.51B | $1.65B | $1.56B | $1.44B |
| GERMANY | $51.00M | $54.00M | $50.00M | $53.00M | $45.00M | $44.00M | $43.00M | $46.00M | $43.00M | $48.00M | $47.00M | $50.00M | $38.00M | $47.00M | $38.00M | $40.00M | $34.00M | $42.00M | $35.00M | $37.00M |
Zoetis's latest quarterly revenue breakdown by geography, as of Mar 24: Total Geographical Area (55.53%), UNITED STATES (29.76%), BRAZIL (2.58%), CHINA (1.94%), AUSTRALIA (1.87%), CANADA (1.56%), GERMANY (1.31%), MEXICO (1.13%), FRANCE (1.05%), JAPAN (0.95%), SPAIN (0.82%), CHILE (0.79%), and ITALY (0.72%).
Zoetis Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TAK | Takeda Pharmaceutical Company | $4.26T | $1.05T |
| TEVA | Teva Pharmaceutical Industries | $15.85B | $4.16B |
| VTRS | Viatris | $15.43B | $3.66B |
| HLN | Haleon | $11.30B | $2.92B |
| BHC | Bausch Health Companies | $8.76B | $2.40B |
| ZTS | Zoetis | $8.54B | $2.36B |
| ELAN | Elanco Animal Health | $4.42B | $1.21B |
| CTLT | Catalent | $4.38B | $1.07B |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| EBS | Emergent BioSolutions | $1.05B | $254.70M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| ASRT | Assertio | $152.07M | $31.13M |
| ALVO | Alvotech | $91.43M | $12.43M |
| PETQ | PetIQ | $1.10M | $328.94M |
ZTS Revenue FAQ
What is Zoetis’s yearly revenue?
Zoetis's yearly revenue for 2023 was $8.54B, representing an increase of 5.74% compared to 2022. The company's yearly revenue for 2022 was $8.08B, representing an increase of 3.91% compared to 2021. ZTS's yearly revenue for 2021 was $7.78B, representing an increase of 16.49% compared to 2020.
What is Zoetis’s quarterly revenue?
Zoetis's quarterly revenue for Q2 2024 was $2.36B, a 7.81% increase from the previous quarter (Q1 2024), and a 8.30% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $2.19B, a -1.04% decrease from the previous quarter (Q4 2023), and a 9.50% increase year-over-year (Q1 2023). ZTS's quarterly revenue for Q4 2023 was $2.21B, a 2.88% increase from the previous quarter (Q3 2023), and a 8.48% increase year-over-year (Q4 2022).
What is Zoetis’s revenue growth rate?
Zoetis's revenue growth rate for the last 3 years (2021-2023) was 9.88%, and for the last 5 years (2019-2023) was 36.49%.
What are Zoetis’s revenue streams?
Zoetis's revenue streams in c 23 are Other Pharmaceuticals, Vaccines, Total Products and Services, Parasiticides, Other Non Pharmaceuticals, Medicated Feed Additives, Dermatology, Contract Manufacturing and Human Health Diagnostics, Anti-infective Products, and Animal Health Diagnostics. Other Pharmaceuticals generated $1.28B in revenue, accounting 7.52% of the company's total revenue Vaccines generated $1.77B in revenue, accounting 10.41% of the company's total revenue Total Products and Services generated $8.47B in revenue, accounting 49.77% of the company's total revenue Parasiticides generated $1.95B in revenue, accounting 11.45% of the company's total revenue Other Non Pharmaceuticals generated $254M in revenue, accounting 1.49% of the company's total revenue Medicated Feed Additives generated $354M in revenue, accounting 2.08% of the company's total revenue Dermatology generated $1.43B in revenue, accounting 8.39% of the company's total revenue Contract Manufacturing and Human Health Diagnostics generated $78M in revenue, accounting 0.46% of the company's total revenue, down -9.30% year-over-year. Anti-infective Products generated $1.06B in revenue, accounting 6.21% of the company's total revenue Animal Health Diagnostics generated $376M in revenue, accounting 2.21% of the company's total revenue
What is Zoetis’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Zoetis was Total Products and Services. This segment made a revenue of $8.47B, representing 49.77% of the company's total revenue.